anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

196,021-196,080 of 319,975

filter-aware
53
The slide uses a circular flow diagram to suggest a cycle of improvement or replacement of existing therapies.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
54
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
55
The slide illustrates the CARDIS platform workflow and the resulting distribution of binders vs non-binders.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
56
The slide uses a biological process diagram to explain the therapeutic mechanism of iNKT cells.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
57
The slide highlights the scalability of the manufacturing process by showing the enrichment of iNKT cells.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
58
The slide uses a three-column layout to explain the discovery, mechanism of action, and manufacturing scalability of the MiNK-413 therapy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
59
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
60
The slide uses a contrast-pairs framework to highlight the competitive advantage of the company's technology.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
61
The slide outlines a three-stage process: Cell expansion, Harvest & Purification, and Formulating & Fill/Finish.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
62
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
63
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
64
The slide uses a 'Our World in Data' chart to provide context for the mortality rates listed on the left.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
65
The diagram illustrates the biological mechanism of iNKT cells interacting with other immune cells (DC, MDSC, Inflammatory Monocyte) to control secondary bacterial pneumonia and inflammation.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
66
The slide uses a combination of medical illustration and real-world clinical photography to explain the procedure.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
67
Clinical trial data summary table.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
68
The slide uses a Kaplan-Meier survival curve, a frequency table for adverse events, and box-and-whisker plots for cytokine levels.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
69
Data presented by Saint John's Cancer Institute for MiNK Therapeutics.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
70
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
71
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
72
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
73
The slide uses a dual-panel layout to contrast pro-inflammatory responses in solid tumors with anti-inflammatory responses in ARDS.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
74
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
75
The slide uses a visual contrast between conventional T cells (left) and innate T cells (right, boxed) to highlight the research gap.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
76
The slide uses a numbered list format to categorize distinct barriers: tumor heterogeneity, trafficking, microenvironment, and product quality.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
77
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
78
The slide uses a visual metaphor of a competition with a trophy to declare iNKT the winner.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
79
The slide uses a visual comparison framework to contrast iNKT cell capabilities against traditional ACT limitations.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
80
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
81
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
82
The slide depicts a mechanism of immune evasion via metabolic competition and immunosuppressive signaling.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
83
The slide uses scRNA-seq data to correlate cell states (Steady State, 4h, 72h post-activation) with specific metabolic gene modules.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
84
Includes a cartoon illustration of a person cooking, likely representing a researcher or experimental process.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
85
The slide depicts a xenograft model setup.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
86
Flow cytometry plots show higher purity/persistence for Gen 2. Bar charts show statistically significant differences (*) in cell count, tumor volume, and metabolic markers.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
87
Uses a visual metaphor to explain biological versatility.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
88
The slide uses UMAP dimensionality reduction to visualize gene expression density across cell populations.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
89
Scientific visualization of immune cell behavior in adipose tissue.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
90
Data from Lynch et al. Nature Immunology 2015 and Lynch et al. Immunity 2012.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
91
The Swiss Army knife is a visual metaphor for the versatility of the cells.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
92
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations 1 hit
01
Slide 1
Morgan Stanley | Fixed Income Presentation Deck | 11 slidesMorgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
02
Morgan Stanley | Fixed Income Presentation Deck | 11 slidesMorgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
03
Includes footnotes referencing specific financial metrics and reporting periods.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
04
Includes four charts: two bar charts, one stacked bar chart, and one donut chart.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
05
The slide includes a stacked bar chart showing funding composition from 2017 to 3Q22, alongside descriptive boxes for each funding category.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
06
Includes footnotes referencing specific financial metrics and regulatory ratios.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
07
Includes stacked bar chart for historical growth, pie chart for loan composition, and table for credit quality metrics.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
08
The slide provides a snapshot of creditworthiness across different debt instruments and entities.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
09
Includes references to E*TRADE and Eaton Vance acquisitions.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
10
This slide serves as a technical appendix for slides 3, 4, 5, 6, and 7.Morgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
11
Morgan Stanley | Fixed Income Presentation Deck | 11 slidesMorgan Stanley | Fixed Income Presentation Deck | 11 slides · Morgan Stanley
Conference presentation Investor relations 1 hit
01
Slide 1
Includes standard regulatory filing disclaimer and exhibit reference.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Situation & Context1 hit
02
Project Orange regulatory filing slide.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Situation & Context1 hit
03
Includes transaction summary, valuation multiples, and implied premia.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Problem & Complication1 hit
04
Project Orange, Preliminary and Confidential Draft.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Problem & Complication1 hit
05
Project Orange preliminary draft.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Problem & Complication1 hit
06
Includes specific investor rollover details and pro forma credit statistics.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Evidence & Proof1 hit
07
Economic ownership calculated off of fully diluted share count of 185.4M inclusive of affiliated shares. Assumes Total Potential Diluted Aggregate Voting Power of 166.9MM votes.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Evidence & Proof1 hit
08
The slide tracks the progression of potential buyers from initial contact through to final bids, with a significant number of parties having passed or not engaged.Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Evidence & Proof1 hit
09
The table uses a color-coded legend for negative outcomes (red X for no interest, double red X for re-confirmed no interest, yellow double X for not engaged).Morgan Stanley | Investment Banking Pitch Book | 28 slides · Morgan Stanley
Regulatory filing Investment bank Beat · Evidence & Proof1 hit